Global Biosimilars Insulin Market Size By Type (Insulin Glargine Basaglar, Insulin Lantus), By Application (Type I Diabetes, Type II Diabetes), By Region, And Segment Forecasts, 2023 to 2032

The Global Biosimilars Insulin Market was valued at USD 3.1 billion in 2023 and is projected to reach USD 7.6 billion by 2031, growing at a CAGR of 12.1% during the forecast period from 2023 to 2031. This growth is attributed to the rising prevalence of diabetes globally, increasing demand for cost-effective treatment options, and the patent expiration of key biologic insulin brands. Biosimilar insulins offer comparable safety and efficacy to originator products but at significantly lower costs, thus enhancing accessibility in both developed and emerging economies. Favorable regulatory pathways and growing healthcare expenditures are also contributing to market expansion.

Drivers

1. Increasing Global Diabetes Burden:

The growing incidence of type 1 and type 2 diabetes worldwide, particularly in low- and middle-income countries, is boosting demand for affordable insulin therapies. This shift is paving the way for biosimilar insulin products to become mainstream in diabetes management.

2. Patent Expirations of Originator Insulins:

As patents for branded biologic insulin products expire, biosimilar manufacturers are entering the market, offering lower-cost alternatives. This dynamic is driving competitive pricing and increased adoption of biosimilars by healthcare providers.

3. Supportive Regulatory Frameworks:

Health authorities like the FDA (U.S.) and EMA (Europe) have streamlined approval processes for biosimilars, facilitating quicker market access and bolstering industry confidence.

Restraints

1. High Manufacturing Complexity and Costs:

Despite lower prices for end-users, developing biosimilars involves complex manufacturing processes that require significant investment in R&D, regulatory compliance, and quality assurance.

2. Physician and Patient Hesitancy:

There is still some reluctance among physicians and patients to switch from originator insulins to biosimilars due to concerns about efficacy, interchangeability, and long-term safety, potentially slowing market penetration.

Opportunity

1. Expansion in Emerging Markets:

Emerging economies, particularly in Asia-Pacific and Latin America, represent untapped opportunities due to their rising diabetic populations, increasing healthcare access, and governmental initiatives to reduce treatment costs.

2. Collaborations and Licensing Agreements:

Strategic partnerships between biosimilar developers and established pharmaceutical companies are enabling faster development, efficient distribution, and expanded market presence.

Market by System Type Insights

The Rapid-acting Biosimilar Insulin segment led the market in 2023, driven by high demand for fast-onset glucose regulation among type 1 diabetics. However, the Long-acting Biosimilar Insulin segment is anticipated to exhibit the highest CAGR during the forecast period, owing to its growing adoption in type 2 diabetes management and improved patient compliance due to reduced injection frequency.

Market by End-use Insights

Hospital Pharmacies accounted for the largest market share in 2023, primarily due to the institutional use of insulin therapy and bulk procurement practices. Retail Pharmacies are expected to gain traction due to increasing outpatient treatment and better accessibility in rural and semi-urban regions.

Market by Regional Insights

North America dominated the global biosimilars insulin market in 2023, benefiting from advanced healthcare infrastructure, high insulin demand, and proactive regulatory policies. However, Asia-Pacific is forecast to witness the fastest growth, spurred by an increasing diabetic population, expanding healthcare access, and strong government support for generic and biosimilar drug adoption.

Competitive Scenario

Key players in the Global Biosimilars Insulin Market include Biocon Biologics, Eli Lilly and Company, Sanofi, Novo Nordisk, Pfizer Inc., Boehringer Ingelheim, Mylan N.V. (Viatris), and Samsung Bioepis. These companies are focusing on biosimilar pipeline expansion, regulatory approvals, strategic collaborations, and geographical expansion to strengthen their market positions.

Scope of Work – Global Biosimilars Insulin Market

Key Market Developments

2023: Biocon Biologics secured FDA approval for its interchangeable biosimilar insulin glargine product, boosting market presence in the U.S.

2024: Pfizer and Samsung Bioepis expanded their distribution partnership to introduce biosimilar insulin products across Latin America and Southeast Asia.

2025: Eli Lilly launched a low-cost biosimilar insulin in the European market targeting underserved diabetic populations.

FAQs

1. What is the current market size of the Global Biosimilars Insulin Market?

The market was valued at USD 3.1 billion in 2023.

2. What is the major growth driver of the Global Biosimilars Insulin Market?

The increasing global prevalence of diabetes and the expiration of patents for originator insulins are key drivers.

3. Which is the largest region during the forecast period in the Global Biosimilars Insulin Market?

North America held the largest share in 2023, while Asia-Pacific is expected to grow fastest.

4. Which segment accounted for the largest market share in the Global Biosimilars Insulin Market?

The Rapid-acting Biosimilar Insulin segment accounted for the largest share in 2023.

5. Who are the key market players in the Global Biosimilars Insulin Market?

Key players include Biocon Biologics, Eli Lilly and Company, Sanofi, Novo Nordisk, Pfizer Inc., and Samsung Bioepis.